Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
5.21
+0.05 (1.06%)
Dec 27, 2024, 10:04 AM EST - Market open
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases.
It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.
The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Annovis Bio, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Maria Maccecchini |
Contact Details
Address: 101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 United States | |
| Phone | (484) 875-3192 |
| Website | annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark K. White | Chief Business Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 424B5 | Filing |
| Dec 9, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Oct 15, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |